12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Xiaflex: Completed Phase IIIb enrollment

Auxilium disclosed in its 2Q13 earnings that it completed enrollment of 725 patients in an open-label, U.S. Phase IIIb trial to evaluate 2 concurrent injections of Xiaflex into palpable cords on the same or different fingers of the affected hand. At the 60-day follow up visit, subjects may receive 3 additional Xiaflex injections.

The product is approved in the U.S. as Xiaflex and as Xiapex in...

Read the full 314 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >